Literature DB >> 12173370

Racial differences in prevalence of a supratypic HLA-genetic marker immaterial to pre-employment testing for susceptibility to chronic beryllium disease.

Ainsley Weston1, James Ensey, Kathleen Kreiss, Channa Keshava, Erin McCanlies.   

Abstract

BACKGROUND: A beryllium materials manufacturer is conducting a limited pilot program that offers testing for HLA-DP beta 1E69 with genetic counseling through a third party to applicants for employment. An important consideration in this regard is the prevalence of this marker in the general population, and its consequent positive predictive value of disease susceptibility.
METHODS: Polymerase chain reaction and restriction fragment length polymorphism analyses were used to determine HLA-DP beta 1E69 population frequencies. Estimation of positive predictive values assumed a disease frequency among beryllium workers of either 5 or 15% and used an odds ratio for disease risk of 35 for the HLA-DP beta 1E69 marker.
RESULTS: Allelic/carrier frequencies were found to be 0.21/0.33, 0.24/0.40, 0.27/0.47, and 0.38/0.59 for Caucasians, African-Americans, Hispanics, and Chinese, respectively. Ranges of positive predictive values for a genetic test based on HLA-DP beta 1E69 in these populations were calculated to be 8.3-14.3% for carriers with an assumed disease frequency of 5%. For high risk subgroups with disease frequencies of 15%, the range of positive predictive values was found to span between 24.9-43.0%.
CONCLUSIONS: These estimates suggest that using HLA-DP beta 1E69 genotyping for general pre-employment screening in the beryllium industry has a low positive predictive value, which varies little among racial groups where carrier frequencies differ significantly.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12173370     DOI: 10.1002/ajim.10072

Source DB:  PubMed          Journal:  Am J Ind Med        ISSN: 0271-3586            Impact factor:   2.214


  6 in total

Review 1.  Clinical application of beryllium lymphocyte proliferation testing.

Authors:  Barbara P Barna; Daniel A Culver; Belinda Yen-Lieberman; Raed A Dweik; Mary Jane Thomassen
Journal:  Clin Diagn Lab Immunol       Date:  2003-11

2.  Surveillance in occupational health.

Authors:  D Koh; T-C Aw
Journal:  Occup Environ Med       Date:  2003-09       Impact factor: 4.402

3.  Research to Practice Implications of High-Risk Genotypes for Beryllium Sensitization and Disease.

Authors:  Kathleen Kreiss; Ethan D Fechter-Leggett; Erin C McCanlies; Christine R Schuler; Ainsley Weston
Journal:  J Occup Environ Med       Date:  2016-09       Impact factor: 2.162

4.  Racial differences in beliefs about genetic screening among patients at inner-city neighborhood health centers.

Authors:  Richard K Zimmerman; Melissa Tabbarah; Mary Patricia Nowalk; Mahlon Raymund; Ilene K Jewell; Stephen A Wilson; Edmund M Ricci
Journal:  J Natl Med Assoc       Date:  2006-03       Impact factor: 1.798

5.  Risk of chronic beryllium disease by HLA-DPB1 E69 genotype and beryllium exposure in nuclear workers.

Authors:  Mike V Van Dyke; John W Martyny; Margaret M Mroz; Lori J Silveira; Matt Strand; Tasha E Fingerlin; Hiroe Sato; Lee S Newman; Lisa A Maier
Journal:  Am J Respir Crit Care Med       Date:  2011-03-11       Impact factor: 21.405

6.  Genetic variability in susceptibility to occupational respiratory sensitization.

Authors:  Berran Yucesoy; Victor J Johnson
Journal:  J Allergy (Cairo)       Date:  2011-06-12
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.